AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
6,442.00
+4.00 (+0.06%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close6,438.00
Open6,417.00
Bid6,450.00 x 6100
Ask6,451.00 x 13000
Day's Range6,388.00 - 6,477.00
52 Week Range5,110.00 - 6,545.00
Volume1,140,222
Avg. Volume2,480,524
Market Cap84.505B
Beta (3Y Monthly)1.11
PE Ratio (TTM)33.91
EPS (TTM)190.00
Earnings DateJul 25, 2019
Forward Dividend & Yield2.15 (3.34%)
Ex-Dividend Date2019-02-28
1y Target Est78.83
  • Financial Times5 days ago

    Investors Chronicle: Telecom Plus, International Consolidated Airlines, AstraZeneca

    Andrew Lindsay, chief executive of Telecom Plus, calls the 12-month period to March 2019 “a turnaround year” from five years of “slowly reducing growth rates”. Customer numbers rose by 4 per cent to 635,039, and the group supplied 2.5m services to its club members — up by 8.2 per cent.

  • How AstraZeneca Is Advancing Its Oncology Portfolio in 2019
    Market Realist8 days ago

    How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

    On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.

  • AstraZeneca’s Lynparza Continues to Dominate
    Market Realist8 days ago

    AstraZeneca’s Lynparza Continues to Dominate

    In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.

  • AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
    Reuters8 days ago

    AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

    Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co , can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said. BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.

  • Reuters8 days ago

    UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

    British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.

  • Tagrisso: AstraZeneca’s Top-Selling Drug in Q1
    Market Realist9 days ago

    Tagrisso: AstraZeneca’s Top-Selling Drug in Q1

    AstraZeneca's (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.

  • How Are AstraZeneca’s Revenues Trending in 2019?
    Market Realist9 days ago

    How Are AstraZeneca’s Revenues Trending in 2019?

    On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.

  • What Analysts Recommend for Merck and AstraZeneca in June
    Market Realist9 days ago

    What Analysts Recommend for Merck and AstraZeneca in June

    Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.

  • CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Business Wire11 days ago

    CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

    An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine

  • Is AstraZeneca plc  (AZN) A Good Stock To Buy?
    Insider Monkey12 days ago

    Is AstraZeneca plc (AZN) A Good Stock To Buy?

    At Insider Monkey we follow nearly 750 of the best-performing investors and even though many of them lost money in the last couple of months of 2018 (some actually delivered very strong returns), the history teaches us that over the long-run they still manage to beat the market, which is why it can be profitable […]

  • Business Wire12 days ago

    LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis

    In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo

  • Business Wire16 days ago

    FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

    FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58

  • What Kind Of Shareholders Own AstraZeneca PLC (LON:AZN)?
    Simply Wall St.16 days ago

    What Kind Of Shareholders Own AstraZeneca PLC (LON:AZN)?

    A look at the shareholders of AstraZeneca PLC (LON:AZN) can tell us which group is most powerful. Institutions will...

  • Reuters23 days ago

    AstraZeneca searches for successor to Chairman Johansson - Sky News

    British drugmaker AstraZeneca Plc is preparing to search for a successor to Chairman Leif Johansson, Sky News reported https://bit.ly/2Zals8B on Monday. AstraZeneca's board is in the early stages of planning for an eventual replacement for Johansson, who has chaired the company for seven years, according to the report. There was no scheduled timetable in place yet for Johansson's departure, Sky News reported, citing sources.

  • Reuters23 days ago

    PRESS DIGEST- Financial Times - June 3

    The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Private equity firms circle Bayer's animal medicine unit ...

  • Reuters24 days ago

    Lynparza stalls pancreatic cancer in patients with BRCA mutations -study

    AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday. BRCA mutations are typically linked with breast and ovarian cancers, but occur in other cancers as well. Lynparza was tested against a placebo as a maintenance therapy in 154 patients with metastatic pancreatic cancer whose tumors had not progressed after chemotherapy.

  • Business Wire24 days ago

    IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer

    Data presented at ASCO 2019 showed 57% of patients alive at three years vs. 43.5% on placebo

  • Why Inovio Pharmaceuticals Stock Is Sinking Today
    Motley Fool26 days ago

    Why Inovio Pharmaceuticals Stock Is Sinking Today

    The small biotech continued to feel the impact of a decision by its big partner.

  • MarketWatch29 days ago

    Inovio Pharma stock slips as AstraZeneca unit scales back agreement

    Inovio Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer said that one of its partners is scaling back on a research collaboration. Inovio shares fell 6.7% after hours, following a 3.7% decline to close at $3.14. In a filing with the Securities and Exchange Commission, Inovio said AstraZeneca PLC subsidiary MedImmune is discontinuing a research agreement with the company with the exception of a drug candidate known as "MEDI0457." The companies will continue evaluating the drug for use in cancers associated with human papillomavirus, or HPV, and Inovio will be eligible for milestone payments should the drug receive market approval.

  • Gaithersburg’s Viela Bio strikes $220M deal with Chinese drug company
    American City Business Journals29 days ago

    Gaithersburg’s Viela Bio strikes $220M deal with Chinese drug company

    It's the local company's first step toward establishing an international presence after it was spun out last year from MedImmune.

  • Tesla, General Motors, Alibaba, and More: Why These Stocks Are in the Spotlight
    Insider Monkey29 days ago

    Tesla, General Motors, Alibaba, and More: Why These Stocks Are in the Spotlight

    The extended weekend is now over, and Wall Street is once again paying attention to the U.S. China trade war, the Indian stock market now that Modi has been reelected as well as various economic indicators. Among the stocks trending this weekend are Alibaba Group Holding Limited (NYSE:BABA), General Motors Company (NYSE:GM), Tesla Inc. (NASDAQ:TSLA), MGM Resorts International (NYSE:MGM), […]

  • Business Wirelast month

    Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative to Empower and Unite Heart Attack Survivors Nationwide

    AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite heart attack survivors nationwide and elevate the importance of daily heart health management. The tour will kick off with a stop in Tampa, Florida, on June 5th, connecting local survivors with Bob Harper to share stories of strength and resilience. Further, the Survivors Have Heart initiative will bring together cardiovascular patient advocacy organizations, healthcare providers, policymakers and other community leaders to celebrate survivorship and champion the importance of cardiovascular health as part of a long-term healthy lifestyle.